Openbookopenbook
Equity
GKOS
+0.0 · +0.00%
USD · NYSE

Glaukos Corp(GKOS) Stock Analysis | Healthcare

USD --+0.00%
Reward59Moderate
Risk44Moderate
75%Data
Thin -31% profit margin · Revenue growing 50% YoY
Profitless Growth
Market Cap:10.91Bn
ⓘ
Reward Rating
59
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
44
Moderate
Risk Assessment
5 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on GKOS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for GKOS, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $197.15.

What is Glaukos Corp?

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.

GKOS · Verdict

Solid reward · moderate risk

GKOS stands out on growth and volatility, but watch the cash flow signal.

Based on 88% data coverage

GKOS · Verdict

What’s working & what to watch

Strengths 2

  • Growth81/100

    Rev +21.5% CAGR · earnings +23.7%

  • Volatility65/100

    Above average

Watchouts 2

  • Cash flow29/100

    -11% free-cash-flow margin

  • Profitability32/100

    -37% net margin · -26% ROE

Model-based scoring. For information only — not financial advice.

What is Glaukos Corp?

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 10.91B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (59)

The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

OCPNFLarge Cap / 10.6B market cap
Olympus Corporation
Compare
CHEOFLarge Cap / 11.6B market cap
Cochlear Limited
Compare
GMEDLarge Cap / 11.7B market cap
Globus Medical
Compare
Company Information
SectorHealthcare
IndustryMedical Devices
Market Cap10.91B
P/E RatioN/A
Dividend YieldN/A
Beta0.762
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
34,657 shares
$489k
0
6-9months
7325,000 shares
$37.7M
0
9-12months
219,655 shares
$1.8M
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.